XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.25.2

Note 5 - Certain Balance Sheet Accounts | 6 Months Ended
--- | ---
Jun. 30, 2025
Notes to Financial Statements |
Supplemental Balance Sheet Disclosures [Text Block] | Note 5 — Certain Balance Sheet Accounts OMIDRIA Contract Royalty Asset The OMIDRIA contract royalty asset consists of the following:
​ |  | June 30, |  |  | December 31, |
​ |  | 2025 |  |  | 2024 |
​ |  | (In thousands) |
Short-term contract royalty asset |  | $ | 28,221 |  |  | $ | 29,083 |
Long-term contract royalty asset |  |  | 114,735 |  |  |  | 124,266 |
Total OMIDRIA contract royalty asset |  | $ | 142,956 |  |  | $ | 153,349 |
See “Note 7 — Discontinued Operations – Sale of OMIDRIA” for discussion regarding the estimated fair value of our OMIDRIA contract royalty asset. Receivables Receivables consist of the following:
​ |  | June 30, |  |  | December 31, |
​ |  | 2025 |  |  | 2024 |
​ |  | (In thousands) |
OMIDRIA royalty receivables |  | $ | 5,210 |  |  | $ | 6,940 |
Other receivables |  |  | 1,066 |  |  |  | 799 |
Total receivables |  | $ | 6,276 |  |  | $ | 7,739 |
Property and Equipment, Net Property and equipment, net consists of the following:
​ |  | June 30, |  |  | December 31, |
​ |  | 2025 |  |  | 2024 |
​ |  | (In thousands) |
Equipment under finance lease obligations |  | $ | 8,324 |  |  | $ | 8,323 |
Laboratory equipment |  |  | 3,732 |  |  |  | 3,690 |
Computer equipment |  |  | 1,113 |  |  |  | 1,113 |
Office equipment and furniture |  |  | 624 |  |  |  | 624 |
Total cost |  |  | 13,793 |  |  |  | 13,750 |
Less accumulated depreciation and amortization |  |  | (11,554 | ) |  |  | (11,072 | )
Total property and equipment, net |  | $ | 2,239 |  |  | $ | 2,678 |
For each of the three months ended June 30, 2025 and 2024, depreciation and amortization expense was $0.2 million, for both periods, respectively. For the six months ended June 30, 2025 and 2024, depreciation and amortization expense was $0.5 million and $0.4 million, respectively. Accrued Expenses Accrued expenses consist of the following:
​ |  | June 30, |  |  | December 31, |
​ |  | 2025 |  |  | 2024 |
​ |  | (In thousands) |
Employee compensation |  | $ | 11,424 |  |  | $ | 8,868 |
Clinical trials |  |  | 8,141 |  |  |  | 7,100 |
Contract research and development |  |  | 2,743 |  |  |  | 4,334 |
Interest payable |  |  | 2,041 |  |  |  | 2,667 |
Consulting and professional fees |  |  | 1,593 |  |  |  | 2,602 |
Other accrued expenses |  |  | 335 |  |  |  | 434 |
Total accrued expenses |  | $ | 26,277 |  |  | $ | 26,005 |
​

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration